Quoin Pharmaceuticals, Ltd. (QNRX): Nasdaq/NYSE listing notice — Quoin Pharmaceuticals receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Quoin Pharmaceuticals, Ltd.

Nasdaq letter dated April 5, 2023: ADS bid price below $1.00 for 30 consecutive business days.
Company has until October 2, 2023 to regain compliance via closing bid >= $1.00 for 10 consecutive days.
If not compliant by Oct 2, company may request additional 180-day grace period if meeting other listing standards.
No immediate effect on Nasdaq listing; company is working on cure but cannot assure compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Quoin Pharmaceuticals, Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 5, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the closing bid price per American Depositary Share (“ADS”) representing 5,000 ordinary shares of the Company was below the required minimum of $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Rule 5550(a)(2). Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company has a period of one hundred eighty (180) calendar days, or until

View on SEC.gov

Browse all listing & compliance notices →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-23-042859

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.